Sign In
Buy RGNX
$6.69
+0.170 (+2.61%)
At Close: Jun 03, 2026
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
06:36pm, Tuesday, 27'th Feb 2024
Regenxbio (RGNX) came out with a quarterly loss of $1.43 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to loss of $1.38 per share a year ago.
REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
04:05pm, Tuesday, 27'th Feb 2024
Focus on clinical stage AAV Therapeutic product candidates addressing large commercial opportunities and value generation Prioritized pipeline is expected to further progress to pivotal stage and firs
ROCKVILLE, Md. , Feb. 21, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, February 27, 2024, at 4:30 p.m.
Jim Cramer lists his top 10 stocks that have jumped this week
07:45pm, Thursday, 08'th Feb 2024
'Mad Money' host Jim Cramer looks at the stocks that have jumped this week as the bull market continues to run.
REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up
10:40am, Thursday, 08'th Feb 2024
REGENXBIO (RGNX) gains 12% on positive top-line results from the phase I/II/III study of its investigational one-time gene therapy candidate, RGX-121, to treat pediatric patients with Hunter syndrome.
Strength Seen in Regenxbio (RGNX): Can Its 11.7% Jump Turn into More Strength?
05:51am, Thursday, 08'th Feb 2024
Regenxbio (RGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength
Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips
04:38am, Friday, 19'th Jan 2024
REGENXBIO's stock has consistently underperformed, down 26% since May. The company released positive interim data from their Phase II trial for the treatment of wet age-related macular degeneration. T
REGENXBIO Inc. (RGNX) Q3 2023 Earnings Call Transcript
10:26pm, Wednesday, 08'th Nov 2023
REGENXBIO Inc. (NASDAQ:RGNX ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Ken Mills - Chief Executive Officer Steve Pakola
REGENXBIO to Participate in Upcoming Investor Conferences
07:05am, Tuesday, 07'th Nov 2023
ROCKVILLE, Md. , Nov. 7, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences: Stifel 2023 Healthcare Conference Firesid
Regenxbio: Biotech To Watch With 2 Possible Accelerated Approval Pathways
05:33pm, Thursday, 02'nd Nov 2023
Regenxbio Inc. is making progress in its pipeline, aiming to have five gene therapies in late-stage testing or approved by 2025. The company's lead candidate, ABBV-RGX-314, is being developed for the
REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights
07:05am, Wednesday, 01'st Nov 2023
ROCKVILLE, Md. , Nov. 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, November 8, 2023, at 4:30 p.m.
REGENXBIO to Participate in Upcoming Investor Conferences
07:05am, Tuesday, 05'th Sep 2023
ROCKVILLE, Md. , Sept. 5, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Morgan Stanley 21st Annual Global Healt
Regenxbio: RGX-314 Continues Advancing With Solid Financials
01:23am, Thursday, 10'th Aug 2023
REGENXBIO is a biotech company specializing in gene therapy, with a focus on addressing unmet medical needs in genetic disorders. The company's cash position decreased to $415.4 million, but it is pro
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
07:29pm, Wednesday, 02'nd Aug 2023
Regenxbio (RGNX) came out with a quarterly loss of $1.66 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.58 per share a year ago.
REGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational Highlights
07:05am, Wednesday, 26'th Jul 2023
ROCKVILLE, Md. , July 26, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, August 2, 2023, at 4:30 p.m.
